J. Calnan and Associates, one of the largest merit shop construction managers in the Northeast, celebrated the grand opening of a new state-of-the-art facility at 880 Winter Street in Waltham, Massachusetts, for Lyra Therapeutics, a clinical-stage biotechnology company dedicated to addressing unmet medical needs in chronic rhinosinusitis (CRS).
JC&A was proud to join Lyra Therapeutics, along with members of the project team including Boston Properties, Perkins + Will, and BR+A Engineers, for this important celebration. This milestone marks a significant step forward in the company’s mission to develop innovative treatments for patients who suffer from CRS.
The newly inaugurated 52,000 square foot cGMP facility features a cutting-edge 5,000 square foot ISO 7 clean room for manufacturing, along with quality control labs, support labs, and office space.
“The grand opening of Lyra Therapeutics’ new facility at 880 Winter Street is a testament to the power of collaboration and innovation,” said Chet Braun, Partner and Project Executive at JC&A. “We are honored to have played a role in creating a space that will drive important research and improve patient care.”
880 Winter Street, once a standard office building, has undergone a remarkable transformation under the leadership of Boston Properties, along with the support of JC&A, Perkins + Will, and BR+A Engineers. The property now boasts custom suites tailored to the unique needs of leading biotech tenants like Lyra Therapeutics, including Carbon Biosciences, Ensem Therapeutics, Mercy BioAnalytics, and TScan. Amenities include a café, fitness center, and corporate center.
